Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 43, 2010, Pages 18593-18598

  Nabekura, Tsukasa ^a   Shibuya, Kazuko ^a   Takenaka, Eri ^a   Kai, Hirayasu ^a   Shibata, Kai ^a   Yamashita, Yumi ^a   Harada, Kyoichi ^a   Tahara Hanaoka, Satoko ^a   Honda, Shin Ichiro ^a   Shibuya, Akira ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Bone marrow transplant; Costimulation

Indexed keywords

CELL ADHESION MOLECULE; DNAX ACCESSORY MOLECULE 1; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT SURVIVAL; HLA MATCHING; INTESTINE; LIVER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; UPREGULATION; WILD TYPE;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; GRAFT VS HOST DISEASE; INTERFERON-GAMMA; LIGANDS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; TRANSPLANTATION, HOMOLOGOUS;

MUS;

EID: 78649855627     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1005582107     Document Type: Article

References (37)

1. Shlomchik WD (2007) Graft-versus-host disease. Nat Rev Immunol 7:340-352.
2. Blazar BR, Korngold R, Vallera DA (1997) Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 157:79-109.
3. Reddy P, Ferrara JL (2003) Immunobiology of acute graft-versus-host disease. Blood Rev 17:187-194.
4. Shlomchik WD, et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412-415. (Pubitemid 29343964)
5. Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21:403-410.
6. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: Pathobiology and management. Exp Hematol 29:259-277.
7. Zeiser R, Marks R, Bertz H, Finke J (2004) Immunopathogenesis of acute graft-versus-host disease: Implications for novel preventive and therapeutic strategies. Ann Hematol 83:551-565.
8. Tanaka J, Asaka M, Imamura M (2000) T-cell co-signalling molecules in graft-versus-host disease. Ann Hematol 79:283-290. (Pubitemid 30349018)
9. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Vallera DA (1995) Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607-2618.
10. Blazar BR, Taylor PA, Linsley PS, Vallera DA (1994) In vivo blockade of CD28/CTLA4: B7/ BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815-3825.
11. Saito K, et al. (1998) Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 160:4225-4231. (Pubitemid 28217276)
12. Wallace PM, et al. (1994) CTLA4Ig treatment ameliorates the lethality of murine graftversus- host disease across major histocompatibility complex barriers. Transplantation 58:602-610.
13. Devetten MP, Vose JM(2004) Graft-versus-host disease: How to translate new insights into new therapeutic strategies. Biol Blood Marrow Transplant 10:815-825. (Pubitemid 39625303)
14. Davies JK, et al. (2008) Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase 1 studies. Blood 112:2232-2241.
15. Cavazzana-Calvo M, et al. (1996) A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: Prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Société Française de Greffe de Moelle Osseuse. Br J Haematol 93:131-138.
16. Vuorte J, et al. (1999) Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol 162:2353-2357.
17. Shibuya A, et al. (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573-581.
18. Bottino C, et al. (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557-567.
19. Tahara-Hanaoka S, et al. (2004) Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 16:533-538.
20. Baury B, et al. (2003) Identification of secreted CD155 isoforms. Biochem Biophys Res Commun 309:175-182.
21. Maier MK, et al. (2007) The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. Eur J Immunol 37:2214-2225.
22. Lopez M, et al. (1998) The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood 92:4602-4611. (Pubitemid 29005862)
23. Tahara-Hanaoka S, et al. (2006) Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 107:1491-1496. (Pubitemid 43242386)
24. El-Sherbiny YM, et al. (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444-8449.
25. Verhoeven DH, et al. (2008) NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 45:3917-3925.
26. Ravens I, Seth S, Förster R, Bernhardt G (2003) Characterization and identification of Tage4 as the murine orthologue of human poliovirus receptor/CD155. Biochem Biophys Res Commun 312:1364-1371.
27. Chadéneau C, LeCabellec M, LeMoullac B, Meflah K, Denis MG (1996) Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. Int J Cancer 68:817-821.
28. Aoki J, et al. (1997) Mouse homolog of poliovirus receptor-related gene 2 product, mPRR2, mediates homophilic cell aggregation. Exp Cell Res 235:374-384.
29. Morrison ME, Racaniello VR (1992) Molecular cloning and expression of a murine homolog of the human poliovirus receptor gene. J Virol 66:2807-2813.
30. Iguchi-Manaka A, et al. (2008) Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 205:2959-2964.
31. Gilfillan S, et al. (2008) DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205:2965-2973.
32. Shibuya K, et al. (2003) CD226 (DNAM-1) is involved in lymphocyte functionassociated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 198:1829-1839. (Pubitemid 38032116)
33. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE (1994) Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540-3549. (Pubitemid 24352920)
34. Pende D, et al. (2006) Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107:2030-2036.
35. Iwasaki A, et al. (2002) Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: Implications for poliovirus infection. J Infect Dis 186:585-592. (Pubitemid 34925529)
36. Blazar BR, et al. (2003) Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101:3741-3748.
37. Taylor PA, et al. (2005) Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 105:3372-3380.